These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 36597217)
21. Hematopoietic stem cell transplantation for B-thalassemia major with alemtuzumab. Sánchez LM; George A; Friend BD; Bhar S; Sasa G; Doherty EE; Craddock J; Steffin D; Salem B; Yassine K; Omer B; Martinez C; Leung K; Krance RA; John TD Pediatr Hematol Oncol; 2024 May; 41(4):260-272. PubMed ID: 38131101 [TBL] [Abstract][Full Text] [Related]
22. Comparison of ATG-thymoglobulin with ATG-Fresenius for Epstein-Barr virus infections and graft-versus-host-disease in patients with hematological malignances after haploidentical hematopoietic stem cell transplantation: a single-center experience. Zhou L; Gao ZY; Lu DP Ann Hematol; 2020 Jun; 99(6):1389-1400. PubMed ID: 32291495 [TBL] [Abstract][Full Text] [Related]
23. [Hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia]. Liu QF; Sun J; Zhang Y; Liu XL; Xu D; Xu B; Feng R; Meng FY; Zhou SY Ai Zheng; 2004 Apr; 23(4):426-9. PubMed ID: 15087032 [TBL] [Abstract][Full Text] [Related]
24. Post-transplant cyclophosphamide for GVHD prophylaxis in pediatrics with chronic active Epstein-Barr virus infection after haplo-HSCT. Luo R; Zhang X; Wang Y; Man Q; Gu W; Tian Z; Wang J Orphanet J Rare Dis; 2022 Dec; 17(1):422. PubMed ID: 36461028 [TBL] [Abstract][Full Text] [Related]
25. High Risk of Recurrence of Malignancy Noted in Four-day rATG Regimen After Allogeneic PBSCT From Matched Sibling Donors. Wang N; Wang H; Fang S; Du J; Huang S; Li F; Jin X; Jia M; Xu L; Dou L; Liu D Transplant Cell Ther; 2022 Nov; 28(11):769.e1-769.e9. PubMed ID: 35973670 [TBL] [Abstract][Full Text] [Related]
26. The combination of cyclosporine and mycophenolate mofetil is less effective than cyclosporine and methotrexate in the prevention of acute graft-versus host disease after stem-cell transplantation from unrelated donors. Yerushalmi R; Shem-Tov N; Danylesko I; Shouval R; Nagler A; Shimoni A Am J Hematol; 2017 Mar; 92(3):259-268. PubMed ID: 28052467 [TBL] [Abstract][Full Text] [Related]
27. Mycophenolate-based graft versus host disease prophylaxis is not inferior to methotrexate in myeloablative-related donor stem cell transplantation. Hamad N; Shanavas M; Michelis FV; Uhm J; Gupta V; Seftel M; Kuruvilla J; Lipton JH; Messner HA; Kim DD Am J Hematol; 2015 May; 90(5):392-9. PubMed ID: 25615933 [TBL] [Abstract][Full Text] [Related]
28. [Quadruple therapy with CsA, MTX, MMF and ATG for preventing graft-versus-host disease in unrelated donor hematopoietic stem cell transplantation]. Liu QF; Sun J; Zhang Y; Xu D; Liu XL; Xu B; Meng FY; Zhou SY Di Yi Jun Yi Da Xue Xue Bao; 2003 Nov; 23(11):1143-5. PubMed ID: 14625172 [TBL] [Abstract][Full Text] [Related]
29. Efficacy and Safety in Early application of Ruxolinitib for high-risk: Acute lymphoblastic leukemia to prevent GVHD and recurrence after allogeneic hematopoietic stem cell transplantation. Cheng Q; Tang Y; Liu F; Li X; Fang D Transpl Immunol; 2024 Apr; 83():101978. PubMed ID: 38302005 [TBL] [Abstract][Full Text] [Related]
30. Lower dose of ATG combined with basiliximab for haploidentical hematopoietic stem cell transplantation is associated with effective control of GVHD and less CMV viremia. Huang Z; Yan H; Teng Y; Shi W; Xia L Front Immunol; 2022; 13():1017850. PubMed ID: 36458000 [TBL] [Abstract][Full Text] [Related]
32. Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Sahebi F; Eikema DJ; Koster L; Kroger N; Meijer E; van Doesum JA; Rovira M; Koc Y; Angelucci E; Blaise D; Sammassimo S; McDonald A; Arroyo CH; Sanchez JF; Forcade E; Castagna L; Stölzel F; Sanz J; Tischer J; Ciceri F; Valcarcel D; Proia A; Hayden PJ; Beksac M; Yakoub-Agha I; Schönland S Transplant Cell Ther; 2021 Dec; 27(12):999.e1-999.e10. PubMed ID: 34543768 [TBL] [Abstract][Full Text] [Related]
33. [Haploidentical allogenetic hematopoietic stem cell transplantation for X-linked adrenoleukodystrophy]. Chen Y; Zhang XH; Xu LP; Liu KY; Qin J; Yang YL; Huang XJ Beijing Da Xue Xue Bao Yi Xue Ban; 2019 Jun; 51(3):409-413. PubMed ID: 31209410 [TBL] [Abstract][Full Text] [Related]
34. The effect of bone marrow-derived mesenchymal stem cell co-transplantation with hematopoietic stem cells on liver fibrosis alleviation and survival in patients with class III β-thalassemia major. Rostami T; Kasaeian A; Maleki N; Nikbakht M; Kiumarsi A; Tavangar SM; Taheri APH; Mousavi SA; Ghavamzadeh A Stem Cell Res Ther; 2021 Mar; 12(1):213. PubMed ID: 33781314 [TBL] [Abstract][Full Text] [Related]
35. Matched Family versus Alternative Donor Hematopoietic Stem Cell Transplantation for Patients with Thalassemia Major: Experience from a Tertiary Referral Center in South India. Swaminathan VV; Uppuluri R; Patel S; Ravichandran N; Ramanan KM; Vaidhyanathan L; Ramakrishnan B; Jayakumar I; Raj R Biol Blood Marrow Transplant; 2020 Jul; 26(7):1326-1331. PubMed ID: 32200123 [TBL] [Abstract][Full Text] [Related]
37. Efficacy, Toxicity, and Infectious Complications in Ruxolitinib-Treated Patients with Corticosteroid-Refractory Graft-versus-Host Disease after Hematopoietic Cell Transplantation. Abedin S; McKenna E; Chhabra S; Pasquini M; Shah NN; Jerkins J; Baim A; Runaas L; Longo W; Drobyski W; Hari PN; Hamadani M Biol Blood Marrow Transplant; 2019 Aug; 25(8):1689-1694. PubMed ID: 30965140 [TBL] [Abstract][Full Text] [Related]
38. High incidence of severe acute graft-versus-host disease with tacrolimus and mycophenolate mofetil in a large cohort of related and unrelated allogeneic transplantation patients. Al-Kadhimi Z; Gul Z; Chen W; Smith D; Abidi M; Deol A; Ayash L; Lum L; Waller EK; Ratanatharathorn V; Uberti J Biol Blood Marrow Transplant; 2014 Jul; 20(7):979-85. PubMed ID: 24709007 [TBL] [Abstract][Full Text] [Related]
39. Peritransplantation Ruxolitinib Prevents Acute Graft-versus-Host Disease in Patients with Myelofibrosis Undergoing Allogenic Stem Cell Transplantation. Kröger N; Shahnaz Syed Abd Kadir S; Zabelina T; Badbaran A; Christopeit M; Ayuk F; Wolschke C Biol Blood Marrow Transplant; 2018 Oct; 24(10):2152-2156. PubMed ID: 29800615 [TBL] [Abstract][Full Text] [Related]
40. Cyclosporine in combination with mycophenolate mofetil versus methotrexate for graft versus host disease prevention in myeloablative HLA-identical sibling donor allogeneic hematopoietic cell transplantation. Hamilton BK; Rybicki L; Dean R; Majhail NS; Haddad H; Abounader D; Hanna R; Sobecks R; Duong H; Hill BT; Copelan E; Bolwell B; Kalaycio M Am J Hematol; 2015 Feb; 90(2):144-8. PubMed ID: 25353395 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]